Loading...
Loading...
catalent-introduces-cryogenic-capabilities-to-support-growing-demand-for-cell-and-gene-therapy-in-philadelphia
catalent-introduces-cryogenic-capabilities-to-support-growing-demand-for-cell-and-gene-therapy-in-philadelphia

Catalent introduces cryogenic capabilities to support growing demand for cell and gene therapy in Philadelphia

0

As part of a newly made investment, pharmaceuticals company Catlent has introduced cryogenic storage at its clinical supply services facility in Philadelphia to support sponsors developing cell and gene therapies.

Sharing the news on Thursday (15th April), the company said the investment has enabled part of the facility to be dedicated to the safe handling of cell and gene therapy samples, including the installation of cryogenic storage, allowing biological materials to be preserved in liquid nitrogen vapor at temperatures of around -180°C.

The facility also has the ability to package, label and distribute cryogenic materials, ensuring the integrity of the therapies being prepared for clinical trials, and has been designed so that capacity can be rapidly expanded further to meet growing clinical supply needs, as well as future commercial demand.

“Establishing robust clinical supply chain services for cell and gene therapies is complex and challenging, and Catalent has undertaken an in-depth strategic review to evaluate how it can establish a safe, efficient and flexible approach to support this fast-growing area of the industry,” said Ricci Whitlow, President, Catalent Clinical Supply Services.

... to continue reading you must be subscribed

Subscribe Today

Paywall Asset Header Graphic

To access hundreds of features, subscribe today! At a time when the world is forced to go digital more than ever before just to stay connected, discover the in-depth content our subscribers receive every month by subscribing to gasworld.

Please wait...